# Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients

> **NCT05188326** · PHASE3 · COMPLETED · sponsor: **Associazione Qol-one** · enrollment: 54 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Vidaza 100 milligram (mg) injection
- **OTHER:** Best Supportive Care

## Key facts

- **NCT ID:** NCT05188326
- **Lead sponsor:** Associazione Qol-one
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-28
- **Primary completion:** 2021-09-27
- **Final completion:** 2021-09-27
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05188326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05188326, "Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05188326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*